Company news
Jiangsu Aidea Pharmaceutical Group Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Report for Q3 2026
October 29, 2026
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Plan for Repurchasing Shares through Call Auction
October 29, 2026
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Resolutions of the 21st Meeting of the 3rd Board of Directors
October 29, 2026
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Proposal by the Chairman and Actual Controller to Repurchase Company Shares
October 29, 2026
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Drug Clinical Trial Approval Notice for ACC085 Tablets
October 27, 2026
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
October 26, 2026
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Proposed Deregistration of Wholly-owned Subsidiary
October 16, 2026
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for ADC118 Tablets
October 15, 2026
Announcement on Signing the Supplementary Agreement to Conditional Stock Subscription Contract with a Specific Investor and Related Party Transaction
September 17, 2026
Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 7, 2026
Announcement on Failure to Satisfy Exercise Conditions for the 1st Exercise Period under the 2025 Stock Option Incentive Plan and Cancellation of Certain Stock Options
August 28, 2026
Announcement on Pledge of Certain Shares Held by Persons Acting in Concert with the Actual Controller
August 18, 2026
Announcement on Results of Shareholding Increase by the Actual Controller
August 13, 2026
Announcement on Progress of Acquisition of the Minority Shareholder's Equity Interests in Controlled Subsidiary
August 12, 2026
Announcement on Use of Own Funds, Bank Acceptance Bills and Other Methods to Pay Funds Required for Raised Fund Investment Projects and Equivalent Replacement with Raised Funds
July 30, 2026
Announcement on Cancellation of Certain Dedicated Settlement Accounts for Wealth Management Products Purchased with Raised Funds
July 24, 2026
Announcement on Voluntary Disclosure of Obtaining of Drug Registration Approval for Darunavir Tablets
July 23, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial for ADC119 Tablets
July 8, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
June 29, 2026
Announcement on Obtaining Government Subsidies
June 28, 2026
Announcement on Re-signing Tripartite Supervision Agreement over Deposit in Special Account of Raised Funds after Changing Sponsor Institution
June 25, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
June 12, 2026
Announcement on Voluntary Disclosure of Receipt of Approval Notice for the Listing Application of Darunavir Active Pharmaceutical Ingredient
May 24, 2026
Announcement on Re-signing Tripartite Agreement on Supervision over Deposit in Special Account of Raised Funds after Changing Sponsor Institution
May 21, 2026
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
April 29, 2026
Announcement on Progress in Acquisition of Minority Shareholders' Stock Rights of a Holding Subsidiary
April 23, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 20, 2026
Announcement on Progress in Material Asset Reorganization
April 14, 2026
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ACC085 Injection
April 6, 2026
Announcement on Remuneration Plan for Directors and Senior Management Members for 2026
March 30, 2026
Announcement on Cancellation of Special Settlement Accounts for Some Raised Fund Financial Products
March 15, 2026
Announcement on Voluntary Disclosure of Obtained Patent Certificates in Japan
March 3, 2026
Announcement on Penalties or Regulatory Measures Imposed by Securities Regulatory Authorities and Stock Exchanges in the Recent Five Years
March 2, 2026
Announcement on Share Increase Plan of Actual Controller
March 1, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 24, 2026
Announcement on Using Temporarily Idle Raised Funds for Cash Management
February 12, 2026
Announcement on Early Return of Remaining Idle Raised Funds Used to Temporarily Supplement Current Capital
February 6, 2026
Earnings Preannouncement for 2025
January 25, 2026
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADC205 Tablets
January 19, 2026
Indicative Announcement on Disclosure of Plan for Issuing A-Shares to Specific Objects by Summary Procedures in 2026
January 13, 2026
Announcement on Estimated Amount of Daily Related Party Transactions in 2026
December 31, 2025
Announcement on the Voluntary Disclosure of Renewal and Inclusion of Two Innovative Anti-HIV Drugs in the National Medical Insurance Catalog
December 7, 2025
Announcement on Voluntary Disclosure of the Successful Enrollment of the 1st Subject in the Phase III Clinical Trial of ACC017 Tablets
November 7, 2025
Report for Q3 2025
October 30, 2025
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADC118 Tablets
October 28, 2025
Announcement on Voluntary Disclosure of Marketing Authorization Approval Received for Dolutegravir Sodium Active Pharmaceutical Ingredient
October 27, 2025
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADB116 for Injection
October 24, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
October 15, 2025
Notice on Convening the 3rd Extraordinary General Meeting in 2025
September 29, 2025
Announcement on Retirement and Resignation of Core Technical Personnel
September 11, 2025